Emerald Health Pharmaceuticals (EHP) is a San Diego-based biotech company focused on developing novel therapies for neurodegenerative and autoimmune diseases. Their proprietary drug candidates, derived from synthetic cannabidiol (CBD) and cannabigerol (CBG), aim to address unmet medical needs in the treatment of diseases such as multiple sclerosis, systemic sclerosis, Parkinson's disease, and Huntington's disease. Established in 2017, EHP's drug candidates are advancing through the development process for various medical indications.